In a show of the growing emphasis on value-based care, Medtronic PLC has entered into an agreement for its products to be reimbursed by Aetna Inc. based on how well patients do on their self-adjusting insulin pump systems. The device-maker says patients on their pumps manage their disease better, which reduces cost to the insurer. Ultimately, Medtronic wants to expand incentives for patients currently treated with daily insulin injections to adopt the pump systems.
"The agreement will measure health outcomes for those patients that choose to transition to pump therapy using a Medtronic insulin...